Merck and Daiichi Sankyo Withdraw Lung Cancer Filing; DSKYF Near-Term Pressure
Merck and Daiichi Sankyo voluntarily withdrew their US accelerated approval application for an experimental lung cancer therapy. The move could delay potential market access, raise development costs, and alter collaboration economics. Near-term investors may reassess the oncology pipeline, weighing downside risk for DSKYF shares amid the regulatory setback.
View signal analysis